(Bloomberg) -- Teva Pharmaceutical Industries Ltd. won a ruling that could keep its cancer drug Bendeka free from generic competition for more than a decade.

A federal judge in Delaware ruled proposed generic versions of Bendeka by Mylan NV, Fresenius SE’s Fresenius Kabi, closely held Apotex Inc. and Slayback Pharma LLC infringe as many as four Teva patents on the drug, which has generated more than $2 billion in sales since its 2016 launch.

©2020 Bloomberg L.P.